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NMR study of complexes between low molecular mass inhibitors and the West
Nile virus NS2B-NS3 protease
Abstract
The two-component NS2B-NS3 protease of West Nile virus is essential for its replication and presents an
attractive target for drug development. Here, we describe protocols for the high-yield expression of stable
isotope-labelled samples in vivo and in vitro. We also describe the use of NMR spectroscopy to determine
the binding mode of new low molecular mass inhibitors of the West Nile virus NS2B-NS3 protease which
were discovered using high-throughput in vitro screening. Binding to the substrate-binding sites S1 and S3
is confirmed by intermolecular NOEs and comparison with the binding mode of a previously identified low
molecular mass inhibitor. Our results show that all these inhibitors act by occupying the substrate-binding
site of the protease rather than by an allosteric mechanism. In addition, the NS2B polypeptide chain was
found to be positioned near the substrate-binding site, as observed previously in crystal structures of the
protease in complex with peptide inhibitors or bovine pancreatic trypsin inhibitor. This indicates that the
new low molecular mass compounds, although inhibiting the protease, also promote the proteolytically
active conformation of NS2B, which is very different from the crystal structure of the protein without
inhibitor.
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Table S1. PCR primers used in this study to produce different variants of WNV NS2BNS3pro1
1131
1132
1133
1134
13072
13082
13143
13153

5'-PO4-TTAGCTGGTCGATCCCGCGAAATTAATACG-3' (30-mer)
5'-PO4-CCAGCTAACAAAAAACCCCTCAAGACCCG-3' (29-mer)
5'-PO4-TCGATCCCGCGAAATTAATACG-3' (22-mer)
5'-PO4-CAAAAAACCCCTCAAGACCCG-3' (21-mer)
5’-TTTTTTTTCATATGGCTTCTATGACCGGTCATCACCAT
CACCATCACACAGACATGTGGATTGAGAGG-3’ (68-mer)
5’- TTTGAATTCTTATTTCTTCCTCAACATTTCAGGTTCGAAGCC-3’ (42-mer)
5’-GTGATTGGATTGTATGCGAACGGCGTCATC-3’ (30-mer)
5’-GATGACGCCGTTCGCATACAATCCAATCAC-3’ (30-mer)

1

Codons of mutated amino acids are underlined. Mutated bases are shown in bold.
Forward and reverse primers to modify the N-terminus to MASMTGH6-.
3
Forward and reverse primers to generate the G151A mutant of NS3.
2
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Figure S1.

15

N-HSQC spectra of 0.9 mM solutions of

15

N-labelled WNV NS2B-

NS3pro(K96A) at 25 oC, pH 7.0, in the presence of (a) 3 mM 2 or (b) 3 mM 3. The
backbone amide resonance assignments are indicated. 500 was added to NS2B sequence
numbers to distinguish them from those of NS3pro.
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Figure S2. Selected spectral region from

15

N-HSQC spectra showing the effect of

increasing concentrations of 2 on the NMR spectrum of WNV NS2B-NS3pro(K96A).
The spectra were recorded at a 1H NMR frequency of 800 MHz, using a 0.8 mM protein
solution in 20 mM HEPES buffer (pH 7.0) at 25 oC. The concentrations of 2 were 0.0
(red), 0.3 (orange), 0.7 (green), and 1.5 mM (blue). The cross-peaks broadened
significantly at intermediate titration ratios (orange spectrum). Increasing amounts of 2
shift the cross-peak of Val166 high-field along the dotted line. In the absence of 2, it is
broad due to conformational exchange in the protease (red spectrum) and it is below the
lowest contour line plotted at intermediate titration ratios (orange spectrum).
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Figure S3. 15N-HSQC spectra of combinatorially 15N-labelled samples of WNV NS2BNS3pro in the presence of 1. Each sample contained about 50 μM protease and 200 μM
1 (t1max = 32 ms, t2max = 73 ms, Bruker 800 MHz NMR spectrometer). The five 15NHSQC spectra are superimposed, where each spectrum is of a sample containing a
different set of

15

N-labelled amino acids. Red: Leu, Arg, Asp, Asn, Tyr, His, Cys;

yellow: Ala, Lys, Arg, Phe, Gln, Met, Cys, Trp; green: Gly, Ile, Lys, Thr, Asn, His, Trp;
cyan: Ser, Val, Ile, Gln, Tyr, Met, His, Trp; magenta: Glu, Val, Thr, Asp, Phe, Met,
Cys. The spectral region shown contains the most crowded region of the

15

N-HSQC

spectrum, illustrating the improved spectral resolution obtained by combinatorial
labelling.
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Figure S4. 800 MHz 1D 1H-NMR spectra of the compounds 2 and 3 in the absence and
presence of WNV NS2B-NS3pro(K96A) in D2O solution containing 1.5% d6-DMSO.
The d6-DMSO was used to dissolve the compounds and generated the resonance at
about 2.7 ppm. (a) 0.5 mM 2. (b) 0.3 mM 3. (c) 0.6 mM 2 and 0.5 mM 3 in the presence
of 30 μM WNV NS2B-NS3pro(K96A). The changes in chemical shifts compared to
those in the absence of protease show that bound and free ligands are in fast exchange
on the chemical shift time scale. This sample was used for the experiment of Figure 4.
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Figure S5. Superimposition of

15

N-HSQC spectra of 0.3 mM WNV NS2B-

NS3pro(K96A) in the presence of 0.5 mM 3 (blue) and 0.2 mM 3 + 0.4 mM Bz-nKKRH (red). The peptide out-competes 3 by forming a covalent bond with the active-site
serine (Yin et al., Bioorg Med Chem Lett 16, 40-43 (2006); Erbel et al., Nat Struct Mol
Biol 13, 372-373 (2006)). The spectra were recorded under the same conditions as those
of Figure 3. Boxes highlight cross-peaks of residues lining the binding pocket. NS2B
cross-peaks are distinguished from NS3 cross-peaks by adding 500 to their sequence
number.
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Figure S6. Superimposition of 15N-HSQC spectra of 0.1 mM solutions of selectively
15

N-Gly labelled WNV NS2B-NS3pro(G151A) in the absence (red spectrum) and

presence (black spectrum) of 0.2 mM 3. The spectra are indistinguishable, showing that
the G151A mutation abolishes binding of 3.
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